Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON® (Mafenide Acetate, USP) Powder for 5% Topical Solution, 73561 [2022-26057]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 229 / Wednesday, November 30, 2022 / Notices
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance document.
FOR FURTHER INFORMATION CONTACT:
Steven Fleischer, Center for Veterinary
Medicine (HFV–110), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–402–0809,
Steven.Fleischer@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
draft GFI #276 entitled ‘‘Effectiveness of
Anthelmintics: Specific
Recommendations for Products
Proposed for the Prevention of
Heartworm Disease in Dogs.’’ The
recommended approach to demonstrate
substantial evidence of effectiveness of
an investigational new animal drug
intended for the prevention of
heartworm disease in dogs is for the
sponsor to conduct two laboratory dose
confirmation studies and one multisite
field effectiveness study in accordance
with the principles of good clinical
practice as described in GFI #85 (VICH
GL9), ‘‘Good Clinical Practice.’’ This
draft guidance provides detail regarding
FDA’s recommendations for the
effectiveness evaluation of drugs
indicated for the prevention of
heartworm disease caused by Dirofilaria
immitis in dogs. This guidance is
informed by comments FDA received in
response to the ‘‘Evaluation of
Approaches To Demonstrate
Effectiveness of Heartworm
Preventatives for Dogs; Request for
Comments,’’ which published in the
Federal Register on May 24, 2018 (83
FR 24122).
This level 1 draft guidance is being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The draft guidance, when
finalized, will represent the current
thinking of FDA on ‘‘Effectiveness of
Anthelmintics: Specific
Recommendations for Products
Proposed for the Prevention of
Heartworm Disease in Dogs.’’ It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
lotter on DSK11XQN23PROD with NOTICES1
II. Paperwork Reduction Act of 1995
While this guidance contains no
collection of information, it does refer to
previously approved FDA collections of
information. Therefore, clearance by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501–
3521) is not required for this guidance.
VerDate Sep<11>2014
16:58 Nov 29, 2022
Jkt 259001
The previously approved collections of
information are subject to review by
OMB under the PRA. The collections of
information in 21 CFR part 514 have
been approved under OMB control
number 0910–0032.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/animal-veterinary/
guidance-regulations/guidanceindustry, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: November 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–26059 Filed 11–29–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–N–2855]
Mylan Institutional, Inc.; Withdrawal of
Approval of a New Drug Application for
SULFAMYLON® (Mafenide Acetate,
USP) Powder for 5% Topical Solution
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
Frm 00023
Fmt 4703
NDA 019832’s accelerated approval
was ‘‘subject to the requirement that the
applicant study the drug further, to
verify and describe its clinical benefit,
where there is uncertainty as to the
relation of the surrogate endpoint to
clinical benefit, or of the observed
clinical benefit to ultimate outcome’’ (21
CFR 314.510). To date, however, Mylan
has not completed the required
confirmatory study. Mylan
acknowledged in its December 10, 2021,
letter requesting withdrawal of approval
that a successful confirmatory study was
necessary to fulfill the accelerated
approval requirements, but stated that
conducting such a study is not feasible.
Mylan thus requested that NDA 019832
be withdrawn under 21 CFR 314.150(d),
and waived its right to a hearing.
Thus, for the reasons discussed above,
under 21 CFR 314.150(d), approval of
NDA 019832 for SULFAMYLON®
(Mafenide Acetate, USP) Powder for 5%
Topical Solution, and all amendments
and supplements thereto, is withdrawn.
Distribution of SULFAMYLON®
(Mafenide Acetate, USP) Powder for 5%
Topical Solution in interstate commerce
without an approved application is
illegal and subject to regulatory action
(see sections 505(a) and 301(d) of the
FD&C Act (21 U.S.C. 355(a) and 331(d)).
Dated: November 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–26057 Filed 11–29–22; 8:45 am]
The Food and Drug
Administration (FDA) is withdrawing
approval of new drug application (NDA)
019832 for SULFAMYLON® (Mafenide
Acetate, USP) Powder for 5% Topical
Solution, held by Mylan Institutional,
Inc., a Viatris company (Mylan). Mylan
has voluntarily requested withdrawal of
this application and has waived its
opportunity for a hearing.
DATES: Applicable November 30, 2022.
FOR FURTHER INFORMATION CONTACT:
Kristiana Brugger, Office of Regulatory
Policy, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 51, Rm. 6262, Silver Spring,
MD 20993, 301–796–3601.
SUPPLEMENTARY INFORMATION: On June 5,
1998, the Food and Drug Administration
(FDA) approved NDA 019832 for
SULFAMYLON® (Mafenide Acetate,
USP) Powder for 5% Topical Solution,
under the Agency’s accelerated approval
regulations (see generally 21 CFR
subpart H). It was approved for ‘‘for use
as an adjunctive topical antimicrobial
agent to control bacterial infection when
used under moist dressings over meshed
autografts on excised burn wounds.’’
SUMMARY:
PO 00000
73561
Sfmt 4703
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–D–0099]
Questions and Answers Regarding
Food Allergens, Including the Food
Allergen Labeling Requirements of the
Federal Food, Drug, and Cosmetic Act
(Edition 5): Draft Guidance for
Industry; Availability; Agency
Information Collection Activities;
Proposed Collection; Comment
Request; and Questions and Answers
Regarding Food Allergens, Including
the Food Allergen Labeling
Requirements of the Federal Food,
Drug, and Cosmetic Act (Edition 5):
Final Guidance for Industry
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or we) is
announcing the availability of a draft
SUMMARY:
E:\FR\FM\30NON1.SGM
30NON1
]]>Agencies
[Federal Register Volume 87, Number 229 (Wednesday, November 30, 2022)]
[Notices]
[Page 73561]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-2855]
Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug
Application for SULFAMYLON[supreg] (Mafenide Acetate, USP) Powder for
5% Topical Solution
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval
of new drug application (NDA) 019832 for SULFAMYLON[supreg] (Mafenide
Acetate, USP) Powder for 5% Topical Solution, held by Mylan
Institutional, Inc., a Viatris company (Mylan). Mylan has voluntarily
requested withdrawal of this application and has waived its opportunity
for a hearing.
DATES: Applicable November 30, 2022.
FOR FURTHER INFORMATION CONTACT: Kristiana Brugger, Office of
Regulatory Policy, Center for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6262,
Silver Spring, MD 20993, 301-796-3601.
SUPPLEMENTARY INFORMATION: On June 5, 1998, the Food and Drug
Administration (FDA) approved NDA 019832 for SULFAMYLON[supreg]
(Mafenide Acetate, USP) Powder for 5% Topical Solution, under the
Agency's accelerated approval regulations (see generally 21 CFR subpart
H). It was approved for ``for use as an adjunctive topical
antimicrobial agent to control bacterial infection when used under
moist dressings over meshed autografts on excised burn wounds.''
NDA 019832's accelerated approval was ``subject to the requirement
that the applicant study the drug further, to verify and describe its
clinical benefit, where there is uncertainty as to the relation of the
surrogate endpoint to clinical benefit, or of the observed clinical
benefit to ultimate outcome'' (21 CFR 314.510). To date, however, Mylan
has not completed the required confirmatory study. Mylan acknowledged
in its December 10, 2021, letter requesting withdrawal of approval that
a successful confirmatory study was necessary to fulfill the
accelerated approval requirements, but stated that conducting such a
study is not feasible. Mylan thus requested that NDA 019832 be
withdrawn under 21 CFR 314.150(d), and waived its right to a hearing.
Thus, for the reasons discussed above, under 21 CFR 314.150(d),
approval of NDA 019832 for SULFAMYLON[supreg] (Mafenide Acetate, USP)
Powder for 5% Topical Solution, and all amendments and supplements
thereto, is withdrawn. Distribution of SULFAMYLON[supreg] (Mafenide
Acetate, USP) Powder for 5% Topical Solution in interstate commerce
without an approved application is illegal and subject to regulatory
action (see sections 505(a) and 301(d) of the FD&C Act (21 U.S.C.
355(a) and 331(d)).
Dated: November 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-26057 Filed 11-29-22; 8:45 am]
BILLING CODE P
